Proteasome-IN-1

By Targets:	Proteasome (10) ADC Antibody (2) Apoptosis (1) CD38 (2) Ligands for E3 Ligase (3) MDM-2/p53 (1) NF-κB (1) PARP (1) PERK (1) Phosphatase (1) PROTACs (3) Ras (1) SHP2 (1)
By Research Areas:	Cancer (14) Infection (1) Inflammation/Immunology (4) Neurological Disease (2)

Targets Recommended: Proteasome AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139331

20S Proteasome-IN-1	Proteasome	Neurological Disease Inflammation/Immunology Cancer
20S Proteasome-IN-1 is a 26S proteasome inhibitor extracted from patent WO2006128196A2 compound 2. 20S Proteasome-IN-1 has the potential for cancer, immune-related disorders, inflammation, ischemic conditions, neurodegenerative disorders and other diseases research ^[1].

HY-100172

Proteasome-IN-1

Proteasome Cancer

Proteasome-IN-1 is a proteasome inhibitor extracted from patent WO 2013142376 A1.

*Proteasome-IN-1*	Proteasome	Cancer
Proteasome-IN-1 is a *proteasome* inhibitor extracted from patent WO 2013142376 A1.

HY-157212

PARP-1/Proteasome-IN-1	Apoptosis PARP Proteasome	Cancer
PARP-1/Proteasome-IN-1 (compound 42i) is a dual PARP-1 and proteasome inhibitor with significant inhibitory effects on breast cancer. *PARP-1/Proteasome*-IN-1 can downregulate the expression of BRCA1 and RAD51 to inhibit homologous recombination repair function and induce apoptosis ^[1].

HY-157032

Proteasome-IN-5

Proteasome Others

Proteasome-IN-5 (compound 5) is a proteasome inhibitor .
HY-P10003A

iso-VQA-ACC TFA

Proteasome Others

iso-VQA-ACC TFA is a constitutive proteasome substrate .

Proteasome-IN-5	Proteasome	Others
Proteasome-IN-5 (compound 5) is a proteasome inhibitor .

iso-VQA-ACC TFA	Proteasome	Others
iso-VQA-ACC TFA is a constitutive proteasome substrate .

HY-150602

20S Proteasome activator 1	Proteasome	Neurological Disease
20S Proteasome activator 1 is a potent 20S proteasome activator with EC₂₀₀ values of 0.3 μM, 0.7 μM and 1.8 μM for trypsin-like site, chymotrypsin-like site and caspase-like site. 20S Proteasome activator 1 translates well in a cellular system, preventing the accumulation of the pathogenic A53T mutant of α-synuclein. 20S Proteasome activator 1 can be used for researching neurodegenerative diseases ^[1].

HY-N11620

Sadopeptins A

Proteasome Others

Sadopeptins A is a nature product that could be isolated from Streptomyces sp. Sadopeptins A is a potent proteasome inhibitor .
HY-N11621

Sadopeptins B

Proteasome Others

Sadopeptins B is a nature product that could be isolated from Streptomyces sp. Sadopeptins B is a potent proteasome inhibitor .
HY-144980

E3 ligase Ligand 21

Ligands for E3 Ligase Cancer

E3 ligase Ligand 21 (compound 2) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway .

Sadopeptins A	Proteasome	Others
Sadopeptins A is a nature product that could be isolated from Streptomyces sp. Sadopeptins A is a potent proteasome inhibitor .

Sadopeptins B	Proteasome	Others
Sadopeptins B is a nature product that could be isolated from Streptomyces sp. Sadopeptins B is a potent proteasome inhibitor .

E3 ligase Ligand 21	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 21 (compound 2) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway .

HY-144983

E3 ligase Ligand 22	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 22 (compound 139) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway .

HY-144985

E3 ligase Ligand 23	Ligands for E3 Ligase	Cancer
E3 ligase Ligand 23 (compound 17-6) is a cereblon binder for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway .

HY-157230

XIAP antagonist 1

Others Cancer

XIAP antagonist 1 (compound A4) is a XIAP-specific antagonist, XIAP antagonist 1 degradation of XIAP via the ubiquitin-proteasome pathway .

XIAP antagonist 1	Others	Cancer
XIAP antagonist 1 (compound A4) is a XIAP-specific antagonist, XIAP antagonist 1 degradation of XIAP via the ubiquitin-proteasome pathway .

HY-152145

PROTAC SOS1 degrader-3	PROTACs Ras	Cancer
PROTAC SOS1 degrader-3 is a potent PROTAC SOS1 degrader. PROTAC SOS1 degrader-3 effectively targeted SOS1 for degradation through the ubiquitin-proteasome system .

HY-P1258

PSI Proteasome INhibitor 1; Z-Ile-Glu(OtBu)-Ala-Leu-CHO	Proteasome	Infection Cancer
PSI (Proteasome Inhibitor 1) is a potent *proteasome* inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas ^[1].

HY-138284

Avenanthramide-C methyl ester	NF-κB	Inflammation/Immunology
Avenanthramide-C methyl ester is an anti-inflammatory agent and NF-κB inhibitor that inhibits the secretion of pro-inflammatory factors. Avenanthramide-C methyl ester inhibits NF-κB activation by inhibiting IKK and IκB phosphorylation and inhibiting proteasome activity .

HY-19726

NSC59984 1 Publications Verification	MDM-2/p53	Cancer
NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway . NSC59984 acts by targeting GOF-mutant p53 and stimulates p73 to restore the p53 pathway signaling .

HY-150226

Enzyme-IN-1	Proteasome	Inflammation/Immunology
Enzyme-IN-1 (compound 1) is a peptide-based inhibitor of N-terminal nucleophile (Ntn) hydrolases. Specifically, Enzyme-IN-1 inhibits the chymotrypsin-like activity (CT-L) of the 20S proteasome. Enzyme-IN-1 may has potential antiinflammatory properties ^[1].

HY-N2166

Tomatine α-TomatINe; LycopersicIN; TomatIN
Tomatine is a glycoalkaloid, found in the tomato plant (Lycopersicon esculentum Mill.). Tomatine elicits neurotoxicity in RIP1 kinase and caspase-independent manner. Tomatine promotes the upregulation of nuclear apoptosis inducing factor (AIF) in neuroblastoma cells. Tomatine also inhibits 20S proteasome activity .

HY-P9915

Daratumumab 1 Publications Verification Anti-Human CD38, Human Antibody	CD38 ADC Antibody	Inflammation/Immunology Cancer
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .

HY-P9915A

Daratumumab (PBS) 1 Publications Verification Anti-Human CD38, Human Antibody (PBS)	ADC Antibody CD38	Cancer
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .

HY-145162

SHP2-D26	SHP2 PROTACs Phosphatase	Cancer
SHP2-D26 is a first, potent and effective SHP2 degrader. SHP2-D26 induces SHP2 degradation requires binding to VHL-1 and SHP2 proteins. SHP2-D26 is also neddylation- and proteasome-dependent .

HY-144323

YF135	PROTACs PERK	Cancer
YF135 is an efficient and reversible-covalent KRAS ^G12C PROTAC. YF135 is designed and synthesized by tethering KRAS G12C inhibitor 48 (compound 6d) as the ligand, and basing on the scaffold of MRTX849 linkage VHL ligand. YF135 significantly induces the degradation of KRAS ^G12C in a reversible manner and decreases phospho-ERK level through the E3 ligase VHL mediated proteasome pathway .

Cat. No.	Product Name

HY-L050

Ubiquitination Compound Library	286 compounds
Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc. MCE offers a unique collection of 286 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

Ubiquitination Compound Library

286 compounds

Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc.

MCE offers a unique collection of 286 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

Cat. No.	Product Name	Target	Research Area

HY-P1258

PSI Proteasome INhibitor 1; Z-Ile-Glu(OtBu)-Ala-Leu-CHO	Proteasome	Infection Cancer
PSI (Proteasome Inhibitor 1) is a potent *proteasome* inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas ^[1].

HY-P10003A

iso-VQA-ACC TFA

Proteasome Others

iso-VQA-ACC TFA is a constitutive proteasome substrate .

iso-VQA-ACC TFA	Proteasome	Others
iso-VQA-ACC TFA is a constitutive proteasome substrate .

Cat. No.	Product Name	Target	Research Area

HY-P9915

Daratumumab 1 Publications Verification Anti-Human CD38, Human Antibody	CD38 ADC Antibody	Inflammation/Immunology Cancer
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .

HY-P9915A

Daratumumab (PBS) 1 Publications Verification Anti-Human CD38, Human Antibody (PBS)	ADC Antibody CD38	Cancer
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N11620

Sadopeptins A	Structural Classification Monophenols Microorganisms Source classification Phenols	Proteasome
Sadopeptins A is a nature product that could be isolated from Streptomyces sp. Sadopeptins A is a potent proteasome inhibitor .

HY-N11621

Sadopeptins B	Structural Classification Monophenols Microorganisms Source classification Phenols	Proteasome
Sadopeptins B is a nature product that could be isolated from Streptomyces sp. Sadopeptins B is a potent proteasome inhibitor .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products